GB9215633D0 - Novel treatment - Google Patents

Novel treatment

Info

Publication number
GB9215633D0
GB9215633D0 GB929215633A GB9215633A GB9215633D0 GB 9215633 D0 GB9215633 D0 GB 9215633D0 GB 929215633 A GB929215633 A GB 929215633A GB 9215633 A GB9215633 A GB 9215633A GB 9215633 D0 GB9215633 D0 GB 9215633D0
Authority
GB
United Kingdom
Prior art keywords
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929215633A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB929215633A priority Critical patent/GB9215633D0/en
Publication of GB9215633D0 publication Critical patent/GB9215633D0/en
Priority to EP93917883A priority patent/EP0651642A1/en
Priority to PCT/GB1993/001539 priority patent/WO1994002150A1/en
Priority to AU47143/93A priority patent/AU4714393A/en
Priority to JP6504294A priority patent/JPH07509456A/ja
Priority to MX9304435A priority patent/MX9304435A/es
Priority to CN93116874A priority patent/CN1043610C/zh
Priority to ZA935339A priority patent/ZA935339B/xx
Priority to TW082105967A priority patent/TW258663B/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB929215633A 1992-07-23 1992-07-23 Novel treatment Pending GB9215633D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment
EP93917883A EP0651642A1 (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
PCT/GB1993/001539 WO1994002150A1 (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
AU47143/93A AU4714393A (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
JP6504294A JPH07509456A (ja) 1992-07-23 1993-07-21 ２型糖尿病および肥満の治療および予防のための１，３−ジシクロプロピメチル−８−アミノ−キサンチンの使用
MX9304435A MX9304435A (es) 1992-07-23 1993-07-22 Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
CN93116874A CN1043610C (zh) 1992-07-23 1993-07-22 新的治疗剂
ZA935339A ZA935339B (en) 1992-07-23 1993-07-23 Anti-obesity agent
TW082105967A TW258663B (enrdf_load_html_response) 1992-07-23 1993-07-27

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment

Publications (1)

Publication Number Publication Date
GB9215633D0 true GB9215633D0 (en) 1992-09-09

Family

ID=10719151

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929215633A Pending GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment

Country Status (9)

Country Link
EP (1) EP0651642A1 (enrdf_load_html_response)
JP (1) JPH07509456A (enrdf_load_html_response)
CN (1) CN1043610C (enrdf_load_html_response)
AU (1) AU4714393A (enrdf_load_html_response)
GB (1) GB9215633D0 (enrdf_load_html_response)
MX (1) MX9304435A (enrdf_load_html_response)
TW (1) TW258663B (enrdf_load_html_response)
WO (1) WO1994002150A1 (enrdf_load_html_response)
ZA (1) ZA935339B (enrdf_load_html_response)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783408A (en) * 1995-06-07 1998-07-21 Hamilton; Bradford S. Method for screening potential anti-obesity agents
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
DE60225556D1 (de) * 2001-07-03 2008-04-24 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2003024965A2 (en) * 2001-09-19 2003-03-27 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
BRPI0609371A2 (pt) 2005-03-08 2010-03-30 Nycomed Gmbh usos de roflumilast na produção de composições farmacêuticas para o tratamento de diabetes mellitus
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN103951667A (zh) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 多晶型
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds

Also Published As

Publication number Publication date
TW258663B (enrdf_load_html_response) 1995-10-01
AU4714393A (en) 1994-02-14
MX9304435A (es) 1994-04-29
EP0651642A1 (en) 1995-05-10
JPH07509456A (ja) 1995-10-19
CN1043610C (zh) 1999-06-16
CN1114880A (zh) 1996-01-17
WO1994002150A1 (en) 1994-02-03
ZA935339B (en) 1995-01-18

Similar Documents

Publication Publication Date Title
GB9215633D0 (en) Novel treatment
GB9208339D0 (en) Treatment composition
GB9127150D0 (en) Novel treatment
GB9226860D0 (en) Novel treatment
GB9308802D0 (en) Treatment
GB9211148D0 (en) Novel treatment
GB9203039D0 (en) Treatment
GB9225860D0 (en) Novel treatment
GB9226957D0 (en) Novel treatment
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
AP9300527A0 (en) Novel treatment
GB9203637D0 (en) Novel treatment
GB9225859D0 (en) Novel treatment
GB9225862D0 (en) Novel treatment
GB9225956D0 (en) Novel treatment
AP9200456A0 (en) Novel treatment
GB9225961D0 (en) Novel treatment
GB9225963D0 (en) Novel treatment
GB9225964D0 (en) Novel treatment
GB9225957D0 (en) Novel treatment
GB9225948D0 (en) Novel treatment
GB9225881D0 (en) Novel treatment
GB9225863D0 (en) Novel treatment
GB9225959D0 (en) Novel treatment
GB9225861D0 (en) Novel treatment